Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Evogene Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₪18.22 |
52 Week High | ₪39.54 |
52 Week Low | ₪17.88 |
Beta | 1.07 |
11 Month Change | -23.57% |
3 Month Change | -28.58% |
1 Year Change | -52.66% |
33 Year Change | -80.17% |
5 Year Change | -62.16% |
Change since IPO | -84.29% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate
Mar 05Will Evogene (TLV:EVGN) Spend Its Cash Wisely?
Oct 09Will Evogene (TLV:EVGN) Spend Its Cash Wisely?
Jun 26We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate
Mar 13Here's Why We're Watching Evogene's (TLV:EVGN) Cash Burn Situation
Oct 07We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate
Jun 16Will Evogene (TLV:EVGN) Spend Its Cash Wisely?
Mar 02Here's Why We're Not Too Worried About Evogene's (TLV:EVGN) Cash Burn Situation
May 28Companies Like Evogene (TLV:EVGN) Are In A Position To Invest In Growth
Jan 21What Can We Make Of Evogene's (TLV:EVGN) CEO Compensation?
Nov 30Shareholder Returns
EVGN | IL Biotechs | IL Market | |
---|---|---|---|
7D | -19.4% | -1.1% | -1.2% |
1Y | -52.7% | -5.6% | -1.9% |
Return vs Industry: EVGN underperformed the IL Biotechs industry which returned -44.9% over the past year.
Return vs Market: EVGN underperformed the IL Market which returned 0.4% over the past year.
Price Volatility
EVGN volatility | |
---|---|
EVGN Average Weekly Movement | 7.2% |
Biotechs Industry Average Movement | 8.1% |
Market Average Movement | 4.4% |
10% most volatile stocks in IL Market | 7.4% |
10% least volatile stocks in IL Market | 3.0% |
Stable Share Price: EVGN's share price has been volatile over the past 3 months.
Volatility Over Time: EVGN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 142 | Ofer Haviv | www.evogene.com |
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Evogene Ltd. Fundamentals Summary
EVGN fundamental statistics | |
---|---|
Market cap | ₪107.70m |
Earnings (TTM) | -₪78.63m |
Revenue (TTM) | ₪33.65m |
2.7x
P/S Ratio-1.2x
P/E RatioIs EVGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EVGN income statement (TTM) | |
---|---|
Revenue | US$9.19m |
Cost of Revenue | US$1.68m |
Gross Profit | US$7.51m |
Other Expenses | US$28.98m |
Earnings | -US$21.47m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -4.24 |
Gross Margin | 81.72% |
Net Profit Margin | -233.66% |
Debt/Equity Ratio | 0% |
How did EVGN perform over the long term?
See historical performance and comparison